Transfusion and COVID-19

COVID-19 Clinical Trial

— TRANSCOV-19  

Official title:

Transfusion and COVID-19

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05075915
• Other study ID #: 7958
• Status: Recruiting
• Start date: September 1, 2020
• Est. completion date: December 31, 2021

Study information

• Verified date: October 2021
• Source: University Hospital, Strasbourg, France
• Contact: Paul-Michel MERTES, MD, PhD
• Phone: 33 3 69 55 04 44
• Email: paul-michel.mertes[@]chru-strasbourg.fr
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Alsace was particularly and early on affected by SARS-CoV-2 and quickly implemented a reduction in scheduled admissions and non-urgent surgical interventions, making it possible to reduce requests for labile blood products linked to non-urgent surgical procedures. as has been reported in the literature; the population containment measures also led to a major reduction in traffic - and consequently accidents on the public roads. At the same time, other demands for blood products related to activities such as onco-hematology were little affected. Finally, the blood banks have adapted their collection procedure.

To answer these questions, we propose to conduct a retrospective study over two parallel periods of 2019 and 2020 of the consumption of blood products on the one hand and the availability of stocks on the other hand.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 500
• Est. completion date: December 31, 2021
• Est. primary completion date: December 31, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion criteria:

• Adults patient (=18 years old)

• Patients admitted to Strasbourg University Hospitals for suspicion of Covid-19, between February 24 and May 31 of 2019 and 2020

• Labile blood products consumed between February 24 and May 31 of 2019 and 2020

• Subjects not having his opposition, after information, to the reuse of his data for the purposes of this research.

Non-inclusion criteria:

• Patients who expressed opposition to participating in the study

• Patients under legal protection

• Patients under guardianship or curatorship

Related Conditions & MeSH terms

• COVID-19

Locations

Country	Name	City	State
France	Service d'Anesthésie et Réanimation chirurgicale - Hôpitaux Universitaires de Strasbourg	Strasbourg

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Strasbourg, France

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Study of the consumption of labile blood products at Strasbourg University Hospitals, during the two covid-19 periods: from February 24 to May 31, 2019 and 2020		Files analysed retrospectively from from February 24 to May 31, 2019 and from February 24 to May 31, 2020 will be examined]